Xarelto, Bayer

Slowly but steadily, Bayer is starting to emerge from under the cloud cast by litigation over the weed killer.

Eliquis, Bristol Myers Squibb

With Celgene and other acquisition costs in the rearview, Bristol Myers Squibb returned to profitability with a vengeance in 2021.


It might seem like luck for a company to trip over a multi-billion dollar COVID treatment already lurking in its pipeline – but perhaps not so much when that company, Gilead, has been at the leading edge of antiviral R&D for decades.


Targeted business development acquisitions, improvements in R&D and operating performance, and a strengthened post-demerger balance sheet are creating new capacity and flexibility for GSK to invest in growth and innovation for patients and shareholders.

Joaquin Duato, Johnson & Johnson

2022 has been marked by the first year of leadership under CEO Joaquin Duato and the anticipated separation of the company’s consumer health business.


For all its forays elsewhere, diabetes remains the bedrock of Lilly’s business – and, if the Mounjaro launch goes as hoped, will continue to be so for a long time to come.


Merck’s exceptional revenue growth in 2021 and the first half of 2022 came thanks to three big brands, one of which is not even approved by the FDA yet.


A separation of Sandoz via a 100 percent spin-off will create the leading European generics company and a global leader in biosimilars, and a more focused Novartis.

Wegovy, Novo Nordisk

Supply problems with the weight loss drug Wegovy were a stumbling block to growth, but Novo Nordisk has rallied.

Roche rapid antigen test

A strong product pipeline and increased group sales confirm that Roche is on the right growth path.